AR115077A1 - DERIVATIVES OF GIP AND ITS USES - Google Patents

DERIVATIVES OF GIP AND ITS USES

Info

Publication number
AR115077A1
AR115077A1 ARP190101181A ARP190101181A AR115077A1 AR 115077 A1 AR115077 A1 AR 115077A1 AR P190101181 A ARP190101181 A AR P190101181A AR P190101181 A ARP190101181 A AR P190101181A AR 115077 A1 AR115077 A1 AR 115077A1
Authority
AR
Argentina
Prior art keywords
gip
peptides
derivatives
nash
obesity
Prior art date
Application number
ARP190101181A
Other languages
Spanish (es)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR115077A1 publication Critical patent/AR115077A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente se refiere a péptidos que son derivados de análogos del polipéptido insulinotrópico dependiente de la glucosa (GIP) que tienen mejor estabilidad física en solución y un perfil de acción prolongado. Más en particular la presente se refiere a tales péptidos que son agonistas del receptor de GIP y a su uso en el control del peso o para el tratamiento de enfermedades tales como obesidad, diabetes o esteatohepatitis no alcohólica (NASH).This refers to peptides that are derived from glucose-dependent insulinotropic polypeptide (GIP) analogs that have better physical stability in solution and a long-acting profile. More particularly the present relates to such peptides which are GIP receptor agonists and their use in weight control or for the treatment of diseases such as obesity, diabetes or nonalcoholic steatohepatitis (NASH).

ARP190101181A 2018-05-04 2019-05-03 DERIVATIVES OF GIP AND ITS USES AR115077A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862666916P 2018-05-04 2018-05-04

Publications (1)

Publication Number Publication Date
AR115077A1 true AR115077A1 (en) 2020-11-25

Family

ID=73543386

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190101181A AR115077A1 (en) 2018-05-04 2019-05-03 DERIVATIVES OF GIP AND ITS USES

Country Status (1)

Country Link
AR (1) AR115077A1 (en)

Similar Documents

Publication Publication Date Title
CL2020002796A1 (en) Derivatives of gip and uses of these
PE20210162A1 (en) INCRETINE ANALOGS AND THEIR USES
MX2023010869A (en) Glucagon-receptor selective polypeptides and methods of use thereof.
CL2019001465A1 (en) New compounds as trigonal peptide agonists of glp1 / glucagon / gip receptors.
CL2017003185A1 (en) Co-agonist compounds of glucagon and glugacon-like peptide-1 (glp-1)
CO7400885A2 (en) Glucagon analogues
MX2016004907A (en) Glucagon analogues.
PH12016500675B1 (en) Acylated glucagon analogues
MX2016016868A (en) Exendin-4 derivatives as selective glucagon receptor agonists.
CL2014003421A1 (en) Glucagon analogs exhibiting agonist activity at the glusose-dependent insulinotropic peptide receptor (gip): pharmaceutical composition; and method to reduce weight gain or induce weight loss, particularly for the treatment of obesity.
CL2019001683A1 (en) Myostatin, activin, or activin receptor antagonists for use in the treatment of obesity and related conditions.
MX2016013243A (en) Peptidic dual glp-1 / glucagon receptor agonists derived from exendin-4.
PH12014501336A1 (en) Glucagon analogues
UY36779A (en) NEW DERIVATIVES OF EXENDINA-4 AS SPECIFIC DUAL PEPTIDE AGONISTS OF GLP-1 / GLUCAGÓN RECEPTORS
UY33462A (en) GLUCAGON ANALOGS
MX2017012864A (en) Acylated glucagon analogue.
BR112019025606A2 (en) MICRO-NEEDLE SYSTEM FOR THE APPLICATION OF PEPTIDE ANALOGS SIMILAR TO GLUCAGON
CL2020000812A1 (en) Semaglutide in medical therapy.
CO2020002500A2 (en) Novel acylated insulin analogs and uses of these
AR115077A1 (en) DERIVATIVES OF GIP AND ITS USES
ECSP15009978A (en) GLUCAGON ANALOGUES
CO6382136A2 (en) GLUCAGON ANALOGS

Legal Events

Date Code Title Description
FB Suspension of granting procedure